본문 바로가기
KERD
논문KCI 등재

Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues

Hans-Christoph Diener|Christoph Kleinschnitz
대한뇌졸중학회 (The Korean Stroke Society)|2016.05|대한뇌졸중영문학회지 (Journal of stroke)|제18권 제2호|pp. 138-145

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

StrokeAnticoagulantsAtrial fibrillationTransient ischemic attack
주제분류신경과학

초록

Non-vitamin-K oral anticoagulants (NOACs) represent a major advance in the prevention of stroke in patients with atrial fibrillation (AF), offering a similar, if not superior, efficacy and safety profile and several practical advantages over oral vitamin K antagonists (VKAs). The rapid onset of action of the NOACs, their relatively short half-live, and the availability of specific reversal agents may be advantageous when managing acute ischemic strokes, and in the post-stroke, post-transient ischemic attack, and post-intracranial hemorrhage settings. In this review article, we offer practical guidance on the use of NOACs in these settings, focusing on managing the acute event and on initiating or resuming anticoagulation for secondary prevention. We also assess the use of NOACs to prevent stroke and bleeding in patients with AF who have chronic kidney disease, are elderly, or cognitively impaired, and we offer guidance on optimizing the use of NOACs and VKAs in these patient groups in the absence of evidence-based guidelines.

Abstract

Non-vitamin-K oral anticoagulants (NOACs) represent a major advance in the prevention of stroke in patients with atrial fibrillation (AF), offering a similar, if not superior, efficacy and safety profile and several practical advantages over oral vitamin K antagonists (VKAs). The rapid onset of action of the NOACs, their relatively short half-live, and the availability of specific reversal agents may be advantageous when managing acute ischemic strokes, and in the post-stroke, post-transient ischemic attack, and post-intracranial hemorrhage settings. In this review article, we offer practical guidance on the use of NOACs in these settings, focusing on managing the acute event and on initiating or resuming anticoagulation for secondary prevention. We also assess the use of NOACs to prevent stroke and bleeding in patients with AF who have chronic kidney disease, are elderly, or cognitively impaired, and we offer guidance on optimizing the use of NOACs and VKAs in these patient groups in the absence of evidence-based guidelines.

참고문헌 (64)

  1. Hart RG, "Meta-analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation", Ann Intern Med, 146, pp.857~867 (2007)
  2. European Heart Rhythm Association, "Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)", Eur Heart J, 31, pp.2369~2429 (2010)
  3. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
  4. Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
  5. Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
  6. Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
  7. Connolly SJ, "Apixaban in patients with atrial fibrillation", N Engl J Med, 364, pp.806~817 (2011)
  8. Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
  9. Heidbuchel H, "Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation", Europace, 17, pp.1467~1507 (2015)
  10. Diener HC, "Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2", Eur Heart J (2016)
  11. Diener HC, "Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1", Eur Heart J (2016)
  12. Xian Y, "Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator", JAMA, 307, pp.2600~2608 (2012)
  13. Mazya MV, "Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin", Ann Neurol, 74, pp.266~274 (2013)
  14. Douxfils J, "Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate", Thromb Haemost, 107, pp.985~997 (2012)
  15. Ebner M, "Point-of-care testing of coagulation in patients treated with non-vitamin K antagonist oral anticoagulants", Stroke, 46, pp.2741~2747 (2015)
  16. Siegal DM, "Andexanet alfa for the reversal of factor Xa inhibitor activity", N Engl J Med, 373, pp.2413~2424 (2015)
  17. Pollack CV Jr, "Idarucizumab for dabigatran reversal", N Engl J Med, 373, pp.511~520 (2015)
  18. Campbell BC, "Endovascular therapy for ischemic stroke with perfusion-imaging selection", N Engl J Med, 372, pp.1009~1018 (2015)
  19. Goyal M, "Randomized assessment of rapid endovascular treatment of ischemic stroke", N Engl J Med, 372, pp.1019~1030 (2015)
  20. Jovin TG, "Thrombectomy within 8 hours after symptom onset in ischemic stroke", N Engl J Med, 372, pp.2296~2306 (2015)
  21. Saver JL, "Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke", N Engl J Med, 372, pp.2285~2295 (2015)
  22. Berkhemer OA, "A randomized trial of intraarterial treatment for acute ischemic stroke", N Engl J Med, 372, pp.11~20 (2015)
  23. Seiffge DJ, "Recanalization therapies in acute ischemic stroke patients : impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome-a pilot study", Circulation, 132, pp.1261~1269 (2015)
  24. Rozeman AD, "Safety of intra-arterial treatment in acute ischaemic stroke patients on oral anticoagulants. A cohort study and systematic review", Eur J Neurol, 23, pp.290~296 (2016)
  25. European Atrial Fibrillation Trial (EAFT) Study Group, "Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke", Lancet, 342, pp.1255~1262 (1993)
  26. Diener HC, "Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial", Lancet Neurol, 11, pp.225~231 (2012)
  27. Holmes DR Jr, "Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation : a patient-level meta-analysis", J Am Coll Cardiol, 65, pp.2614~2623 (2015)
  28. Taylor DW, "Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators", Lancet, 353, pp.2179~2184 (1999)
  29. Akins PT, "Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation : pooled analysis of SPORTIF III and V clinical trials", Stroke, 38, pp.874~880 (2007)
  30. Rådberg JA, "Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment", Stroke, 22, pp.571~576 (1991)
  31. Flibotte JJ, "Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage", Neurology, 63, pp.1059~1064 (2004)
  32. Hart RG, "Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran : the RE-LY trial", Stroke, 43, pp.1511~1517 (2012)
  33. Hankey GJ, "Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation", Stroke, 45, pp.1304~1312 (2014)
  34. Zhou W, "Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran", Stroke, 42, pp.3594~3599 (2011)
  35. Hankey GJ, "Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned?", Curr Cardiol Rep, 16, pp.480~ (2014)
  36. Niessner A, "Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis", Eur Heart J (2015)
  37. Parry-Jones AR, "Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage", Ann Neurol, 78, pp.54~62 (2015)
  38. Goldstein JN, "Risk of thromboembolism following acute intracerebral hemorrhage", Neurocrit Care, 10, pp.28~34 (2009)
  39. Christensen MC, "Risk of thromboembolic complications after intracerebral hemorrhage according to ethnicity", Adv Ther, 25, pp.831~841 (2008)
  40. Kiphuth IC, "Early administration of low molecular weight heparin after spontaneous intracerebral hemorrhage. A safety analysis", Cerebrovasc Dis, 27, pp.146~150 (2009)
  41. Wu TC, "Pharmacological deep vein thrombosis prophylaxis does not lead to hematoma expansion in intracerebral hemorrhage with intraventricular extension", Stroke, 42, pp.705~709 (2011)
  42. Orken DN, "Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage", Neurologist, 15, pp.329~331 (2009)
  43. Claassen DO, "Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage", Arch Neurol, 65, pp.1313~1318 (2008)
  44. Kuramatsu JB, "Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage", JAMA, 313, pp.824~836 (2015)
  45. Bailey RD, "Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage", Neurology, 56, pp.773~777 (2001)
  46. Charidimou A, "Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk", Front Neurol, 3, pp.133~ (2012)
  47. Saito T, "Non-vitamin k antagonist oral anticoagulants do not increase cerebral microbleeds", J Stroke Cerebrovasc Dis, 24, pp.1373~1377 (2015)
  48. Fox KA, "Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment", Eur Heart J, 32, pp.2387~2394 (2011)
  49. Hohnloser SH, "Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation : insights from the ARISTOTLE trial", Eur Heart J, 33, pp.2821~2830 (2012)
  50. Hijazi Z, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation : a RE-LY(Randomized Evaluation of Long-term Anticoagulation Therapy)trial analysis", Circulation, 129, pp.961~970 (2014)
  51. Eikelboom JW, "Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease", J Stroke Cerebrovasc Dis, 21, pp.429~435 (2012)
  52. Fox KA, "Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment", Eur Heart J, 32, pp.2387~2394 (2011)
  53. Chan KE, "Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis", Circulation, 131, pp.972~979 (2015)
  54. Shah M, "Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis", Circulation, 129, pp.1196~1203 (2014)
  55. Sharma M, "Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism : systematic review and meta-analysis", Circulation, 132, pp.194~204 (2015)
  56. Mant J, "Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial", Lancet, 370, pp.493~503 (2007)
  57. Eikelboom JW, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation : an analysis of the randomized evaluation of long-term anticoagulant therapy(RE-LY)trial", Circulation, 123, pp.2363~2372 (2011)
  58. Halvorsen S, "Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation : observations from the ARISTOTLE trial", Eur Heart J, 35, pp.1864~1872 (2014)
  59. Poli D, "Bleeding risk in very old patients on vitamin K antagonist treatment : results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation", Circulation, 124, pp.824~829 (2011)
  60. Gage BF, "Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall", Am J Med, 118, pp.612~617 (2005)
  61. Kakkar AK, "Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GAR-FIELD registry", PLoS One, 8, pp.e63479~ (2013)
  62. Kakkar AK, "International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)", Am Heart J, 163, pp.13~19.e1 (2012)
  63. Huisman MV, "Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry, Phase II", Am J Med, 128, pp.1306~1313.e1 (2015)
  64. Huisman MV, "Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation : a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation", Am Heart J, 167, pp.329~334 (2014)

관련 논문AI추천

Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical IssuesDavid S Liebeskind, Monica Khunger, UCLA, Los Angeles, United States대한뇌졸중학회 · 대한뇌졸중영문학회지2017 · 제19권 제1호Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke김영대, 나정호, 배희준, 유경호, 윤병우, 이병철, 허지회, Jong-Moo Park, Keun-Hwa Jung, Keun-Sik Hong, Sun U. Kwon대한뇌졸중학회 · 대한뇌졸중영문학회지2015 · 제17권 제2호허혈뇌졸중에서 비타민 K 비의존경구항응고제의 사용박형종, 유준상대한신경과학회 · 대한신경과학회지2022 · 제40권 제1호Occurrence of Ischemic Stroke in Patients With Atrial Fibrillation Receiving Non-Vitamin K Oral Anticoagulants: Causes and Prevention StrategiesDong Seop Jeong, Kyoung-Min Park, Oh Young Bang대한뇌졸중학회 · 대한뇌졸중영문학회지2023 · 제25권 제2호Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation김치경, 윤병우, 정승욱대한뇌졸중학회 · 대한뇌졸중영문학회지2013 · 제15권 제3호Haemorrhagic Transformation after Ischaemic Stroke in Patients Taking Non-vitamin K Antagonist Oral AnticoagulantsFrederick Palm, Jan C. Purrucker, Johannes Meyne, Kirsten Haas, Marcel Wolf, Markus Möhlenbruch, Peter Kraft, Peter U. Heuschmann, Rainer Dziewas, Roland Veltkamp, Sebastian Jander, Shujah Khan, Sven Poli, Timolaos Rizos대한뇌졸중학회 · 대한뇌졸중영문학회지2017 · 제19권 제1호

이 간행물의 다른 논문 (16건)

How and When to Screen for Atrial Fibrillation after Stroke: Insights from Insertable Cardiac Monitoring DevicesFrancesca Bridge, Vincent Thijspp. 121-128The Mechanism of and Preventive Therapy for Stroke in Patients with Atrial Fibrillation노승영, Young-Hoon Kimpp. 129-137The Migraine–Stroke ConnectionMi ji Lee, Chungbin Lee, Chin-Sang Chungpp. 146-156Ischemic Stroke after Heart TransplantationRossana Tassi, Maurizio Acampa, Pietro Enea Lazzerini, Giuseppe Martini, Francesca Guideripp. 157-168Asian Patients with Stroke plus Atrial Fibrillation and the Dose of Non-Vitamin K Oral Anticoagulants허지회, Oh Young Bang, Keun-Sik Hongpp. 169-178
원문 보기